Why the study?
Does PARP inhibitor PJ34 improve endothelial function in aging Wistar rats?
Does PARP inhibitor PJ34 improve endothelial function in aging Wistar rats?
Inhibition of PARP with PJ34 restores endothelial function in aging rats, suggesting intraendothelial PARP activation contributes to age-related endothelial dysfunction.
Answers are grounded in this paper and cite their sources.
Does not support clinical use; hypothesis-generating for PARP inhibition in human endothelial aging.
Recent work has demonstrated the production of reactive oxygen and nitrogen species in the vasculature of aging animals. Oxidant induced cell injury triggers the activation of nuclear enzyme poly(ADP ribose) polymerase (PARP) leading to endothelial dysfunction in various pathophysiological conditions (reperfusion, shock, diabetes). Here we studied whether the loss of endothelial function in aging rats is dependent upon the PARP pathway within the vasculature. Young (3 months-old) and aging (22 months-old) Wistar rats were treated for 2 months with vehicle or the PARP inhibitor PJ34. In the vehicle-treated aging animals there was a significant loss of endothelial function, as measured by the relaxant responsiveness of vascular rings to acetylcholine. Treatment with PJ34, a potent PARP inhibitor, restored normal endothelial function. There was no impairment of the contractile function and endothelium-independent vasodilatation in aging rats. Furthermore, we found no deterioration in the myocardial contractile function in aging animals. Thus, intraendothelial PARP activation may contribute to endothelial dysfunction associated with aging.
No takes yet. Share an insight, caveat, or question.
Pacher et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: